Pfizer Inc. (NYSE:PFE) Shares Sold by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich trimmed its position in Pfizer Inc. (NYSE:PFE) by 0.2% in the fourth quarter, Holdings Channel reports. The firm owned 2,055,639 shares of the biopharmaceutical company’s stock after selling 4,182 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Pfizer were worth $59,182,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of PFE. Briaud Financial Planning Inc acquired a new position in Pfizer in the third quarter worth about $30,000. GoalVest Advisory LLC lifted its holdings in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. bought a new position in Pfizer in the third quarter worth about $34,000. VisionPoint Advisory Group LLC lifted its holdings in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new position in Pfizer in the fourth quarter worth about $36,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Pfizer stock traded down $1.01 during mid-day trading on Thursday, hitting $25.26. The company’s stock had a trading volume of 47,041,425 shares, compared to its average volume of 41,958,969. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $143.04 billion, a P/E ratio of 70.17, a P/E/G ratio of 1.19 and a beta of 0.61. Pfizer Inc. has a twelve month low of $25.23 and a twelve month high of $40.37. The stock’s fifty day moving average price is $27.05 and its two-hundred day moving average price is $28.50.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.14 earnings per share. Research analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.65%. The ex-dividend date is Thursday, May 9th. Pfizer’s payout ratio is 466.67%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.